Device Trial Radar · NCT07278310
STAR Trial (Siegel Transcatheter Aortic Valve Replacement in Patients With Symptomatic Severe Aortic Stenosis)
Last checked: Nov 19, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,025
Planned (sponsor's estimate)
Start
Apr 2026
Primary completion
Apr 2028
Study completion Apr 2028
Sponsor
- Lead sponsor
- MiRusNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 12, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis.
Conditions
- Symptomatic Severe Native Aortic Stenosis
- Aortic Stenosis
Interventions
TAVR DeviceDevice
Commercially available TAVR Device
Siegel TAVR DeviceDevice
Siegel TAVR Device
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause mortality, all stroke and cardiovascular rehospitalizationTime frame: 1 Year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Piedmont Heart Institute
Atlanta, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.